Ftse Mib
34.247,10
0,77%
DAX
18.229,93
0,32%
S&P 500
5.180,74
1,03%
NASDAQ
16.349,25
1,19%
Bitcoin
64.130,08
1,53%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Neoleukin Therapeutics Inc (NLTX) Neoleukin Therapeutics Inc (NLTX) Notizie

Neoleukin Therapeutics Inc

NLTX
3,49
0,00 (0,00%)
Pre Mercato
Ultimo aggiornamento: 02:00:00
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
26/4/202420:34EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
26/4/202420:33EDGAR2Form ARS - Annual Report to Security Holders
26/4/202420:33EDGAR2Form DEF 14A - Other definitive proxy statements
22/4/202422:44EDGAR2Form 8-K - Current report
02/4/202421:43EDGAR2Form 8-K - Current report
18/3/202421:10EDGAR2Form 8-K - Current report
18/3/202421:04EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
15/3/202401:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/3/202401:53EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/3/202401:51EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/3/202422:29EDGAR2Form 144 - Report of proposed sale of securities
05/3/202400:20EDGAR2Form 144 - Report of proposed sale of securities
04/3/202413:30EDGAR2Form 8-K - Current report
21/2/202422:07EDGAR2Form 8-K - Current report
20/2/202422:16EDGAR2Form S-8 - Securities to be offered to employees in employee..
15/2/202400:05EDGAR2Form SC 13G - Statement of acquisition of beneficial..
14/2/202422:26EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14/2/202422:16EDGAR2Form SC 13G - Statement of acquisition of beneficial..
14/2/202421:08EDGAR2Form SC 13G - Statement of acquisition of beneficial..
14/2/202415:19EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
06/2/202422:18EDGAR2Form 144 - Report of proposed sale of securities
19/1/202401:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19/1/202400:58EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19/1/202400:56EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19/1/202400:53EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19/1/202400:48EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19/1/202400:45EDGAR2Form 3 - Initial statement of beneficial ownership of..
05/1/202413:11EDGAR2Form 8-K - Current report
27/12/202300:16EDGAR2Form 3 - Initial statement of beneficial ownership of..
27/12/202300:12EDGAR2Form 3 - Initial statement of beneficial ownership of..
27/12/202300:10EDGAR2Form 3 - Initial statement of beneficial ownership of..
27/12/202300:05EDGAR2Form 3 - Initial statement of beneficial ownership of..
27/12/202300:04EDGAR2Form 3 - Initial statement of beneficial ownership of..
22/12/202322:15EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
21/12/202322:05EDGAR2Form SC 13D - General statement of acquisition of beneficial..
19/12/202313:31EDGAR2Form 8-K - Current report
15/12/202301:00GLOBENeoleukin Therapeutics Announces 1-for-4 Reverse Stock Split
06/12/202322:24EDGAR2Form 425 - Prospectuses and communications, business..
06/12/202322:21EDGAR2Form 8-K - Current report
04/12/202323:14EDGAR2Form 425 - Prospectuses and communications, business..
04/12/202323:10EDGAR2Form 8-K - Current report
30/11/202322:06EDGAR2Form 425 - Prospectuses and communications, business..
08/11/202320:34EDGAR2Form S-4/A - Registration of securities, business..
18/10/202322:09EDGAR2Form S-4/A - Registration of securities, business..
05/10/202318:50EDGAR2Form 425 - Prospectuses and communications, business..
28/9/202322:28EDGAR2Form S-4/A - Registration of securities, business..
22/9/202314:03EDGAR2Form 8-K - Current report
22/9/202314:00GLOBENeoleukin Therapeutics Announces 1-for-5 Reverse Stock Split
14/8/202322:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/8/202322:13EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Apertura: Min: Max:
Chiusura: 3,49

La tua Cronologia

NASDAQ
NLTX
Neoleukin Therapeutics
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network